Brian Callahan, MD
Neurological Surgery · Tucson, AZNPI 1982750576
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Boston Scientific at 47.7% of the total. That places this record below the midpoint for neurological surgery clinicians in AZ, where the typical reported total is $3,798.
Across 58 payments — averaging $12.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$356
- AbbVie$78
- Servier Pharmaceuticals LLC$52
- Argenx US, Inc.$44
- UCB, Inc.$37
- Eisai Inc.$36
- plus $142 from 8 others
Across 7 payments — averaging $32,083 each. An ownership or investment interest held by the physician or an immediate family member.
- Synapse Surgical LLC$225K
What the payments were for
- Food & beverage$746100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 39 | $356 |
| AbbVie | 3 | $78 |
| Servier Pharmaceuticals LLC | 2 | $52 |
| Argenx US, Inc. | 2 | $44 |
| UCB, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $36 |
| SK Life Science, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Biogen | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
How this compares
$746 in reported general payments places this provider in the 25th percentile of 173 neurological surgery providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methocarbamol | 51 | $1,203 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 86 | $758 |
| Oxycodone Hcl | 76 | $677 |
| Gabapentin | 63 | $544 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $365 |
| Pregabalin | 15 | $210 |
| Tizanidine Hcl | 19 | $175 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Tucson
- Richard ChuaTucson$1.3M
- Li-Mei LinTucson$653K
- Ryan KretzerTucson$402K
- Julie PilitsisTucson$165K
- Paul LarsonTucson$96K
- Ibrahim AlhalalTucson$53K
- Timothy PuttyTucson$39K
- Ryan AustermanTucson$37K
- Kirsty HamiltonTucson$37K
- Arunit ChughTucson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.